Analysis of oncological outcomes of whole-gland therapy with high-intensity focused ultrasound for localized prostate cancer in clinical and technical aspects: a retrospective consecutive case-series analysis with a median 5-year follow-up

Reference

• Madersbacher S, Pedevilla M, Vingers L, et al. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res. 1995;55(15):3346–3351.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974.
   PubMed Web of Science ®Google Scholar
• Roach M, 3rd, Hanks G, Thames H, Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974.
   PubMed Web of Science ®Google Scholar
• Uchida T, Tomonaga T, Kim H, et al. Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer. J Urol. 2015;193(1):103–110.
   PubMed Web of Science ®Google Scholar
• Crouzet S, Chapelon JY, Rouviere O, et al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol. 2014;65(5):907–914.
   PubMed Web of Science ®Google Scholar
• He Y, Tan P, He M, et al. The primary treatment of prostate cancer with high-intensity focused ultrasound: A systematic review and meta-analysis. Medicine. 2020;99(41):e22610:
   PubMed Web of Science ®Google Scholar
• Bakarev MA, Levin VP, Kachesov IV, et al. Status of the microcirculatory network as a factor of prognosis and evaluation of therapeutic efficiency in prostate cancer treated by high-intensity focused ultrasound in combination with androgen deprivation. Bull Exp Biol Med. 2018;165(5):682–687.
   PubMed Web of Science ®Google Scholar
• Wiart M, Curiel L, Gelet A, et al. Influence of perfusion on high-intensity focused ultrasound prostate ablation: a first-pass MRI study. Magn Reson Med. 2007;58(1):119–127.
   PubMed Web of Science ®Google Scholar
• Sumitomo M, Hayashi M, Watanabe T, et al. Efficacy of short-term androgen deprivation with high-intensity focused ultrasound in the treatment of prostate cancer in Japan. Urology. 2008;72(6):1335–1340.
   PubMed Web of Science ®Google Scholar
• Shoji S, Hashimoto A, Nakamoto M, et al. Morphological analysis of the effects of intraoperative transrectal compression of the prostate during high-intensity focused ultrasound for localized prostate cancer. Int J Urol. 2015;22(6):563–571.
   PubMed Web of Science ®Google Scholar
• Shoji S, Uchida T, Nakamoto M, et al. Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy. J Urol. 2013;190(4):1224–1232.
   PubMed Web of Science ®Google Scholar
• Shoji SM, Scionti S. High intensity focused ultrasound (HIFU) treatment of prostate cancer. In: Truls Bjerklund Johansen, David J. Breen, Damian Greene, Vladimir Mouraviev, editors. Handbook of focal therapy for prostate and renal cancer. UK: JP Medical LTD; 2016, p. 241–254.
   Google Scholar
• Walz J, Burnett AL, Costello AJ, et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol. 2010;57(2):179–192.
   PubMed Web of Science ®Google Scholar
• Shoji S, Tonooka A, Hashimoto A, et al. Time-dependent change of blood flow in the prostate treated with high-intensity focused ultrasound. Int J Urol. 2014;21(9):942–945.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Dickinson L, Charman S, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol. 2015;68(6):927–936.
   PubMed Web of Science ®Google Scholar
• Feijoo ER, Sivaraman A, Barret E, et al. Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes. Eur Urol. 2016;69(2):214–220.
   PubMed Web of Science ®Google Scholar
• van Velthoven R, Aoun F, Marcelis Q, et al. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(1):79–83.
   PubMed Web of Science ®Google Scholar
• Rischmann P, Gelet A, Riche B, et al. Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. Eur Urol. 2017;71(2):267–273.
   PubMed Web of Science ®Google Scholar
• Guillaumier S, Peters M, Arya M, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74(4):422–429.
   PubMed Web of Science ®Google Scholar
• Ganzer R, Hadaschik B, Pahernik S, et al. Prospective multicenter phase ii study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound. J Urol. 2018;199(4):983–989.
   PubMed Web of Science ®Google Scholar
• Shoji S, Hiraiwa S, Uemura K, et al. Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes. Int J Clin Oncol. 2020;25(10):1844–1853.
   PubMed Web of Science ®Google Scholar
• Abreu AL, Peretsman S, Iwata A, et al. High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series. J Urol. 2020;204(4):741–747.
   PubMed Web of Science ®Google Scholar
• Köllermann J, Feek U, Müller H, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 2000;38(6):714–720.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–2504.
   PubMed Web of Science ®Google Scholar
• Hu JC, Hung SC, Ou YC. Assessments of neoadjuvant hormone therapy followed by robotic-assisted radical prostatectomy for intermediate- and high-risk prostate cancer. Anticancer Res. 2017;37(6):3143–3150.
   PubMed Web of Science ®Google Scholar
• Chapelon JY, Ribault M, Vernier F, et al. Treatment of localised prostate cancer with transrectal high intensity focused ultrasound. Eur J Ultrasound. 1999;9(1):31–38.
   PubMedGoogle Scholar
• Fox M, Thumshirn M, Fruhauf H, et al. Determinants of fecal continence in healthy, continent subjects: a comprehensive analysis by anal manometry, rectal barostat and a stool substitute retention test. Digestion. 2011;83(1-2):46–53.
   PubMed Web of Science ®Google Scholar